<DOC>
	<DOCNO>NCT03096899</DOCNO>
	<brief_summary>The primary objective study estimate overall survival patient receive best supportive care ( BSC ) treatment-resistant , metastatic colorectal carcinoma . The primary efficacy outcome overall survival , define time date radiographic scan demonstrate disease progression post available treatment ( time origin , T0 ) death cause .</brief_summary>
	<brief_title>A Study Estimate Overall Survival Patients Receiving Best Supportive Care Treatment-Resistant , Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description>This retrospective chart review prospective observational study . Patients consider enrollment receive BSC already decide independently study pursue therapeutic treatment cancer . Patients must receive least two prior treatment disease , chemotherapy , target therapy regimen . The study consist administration inform consent , include permission review medical record record relevant medical information , agreement follow survival , evaluation appropriate inclusion/exclusion entry criterion . Patients study-specific assessment perform part study , follow survival . Approximately 80 patient treatment-resistant , metastatic colorectal cancer receive BSC , enter study five site United States</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients must meet follow criterion consider eligible participate study : 1 . Adult men woman , age 18 year old , histologicallyconfirmed , metastatic adenocarcinoma colon rectum resistant available treatment option , include least two option available chemotherapy , target regimen . 2 . Radiographically documented evidence disease progression recent therapy administer prior initiation BSC . 3 . Life expectancy least six week , Investigator 's opinion , time disease progression recent therapy administer prior initiation BSC . 4 . In Investigator 's opinion , surgical candidate time disease progression . Initiation treatment BSC within two month . 5 . Able provide write informed consent ( patient family member health proxy ) . Patients , time disease progression recent therapy administer prior initiation BSC , meet follow criterion exclude participate study : 1 . Documentation hepatic blood flow abnormality , i.e. , portal vein hypertension thrombosis , and/or large volume ascites . 2 . Documentation concurrent cancer type ( Note : patient nonmelanoma skin cancer still consider eligible ) . 3 . Documentation positive test result human immunodeficiency virus ( HIV ) hepatitis ( Hepatitis A ) . 4 . Considered Investigator unsuitable participation study upon review medical history , physical examination clinical laboratory test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>